)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Oncoinvent
Oncoinvent (ONCIN) investor relations material
Oncoinvent Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Feb, 2026
Executive summary
Reported positive final data from Phase I RadspherinⓇ trial in ovarian cancer, published in Gynecologic Oncology and presented at ESGO, showing low peritoneal recurrence at 24 months compared to standard care.
Completed merger with BerGenBio, inheriting Oslo Stock Exchange main board listing and adding NOK 45-51.2 million in cash.
Raised NOK 130 million in equity through a fully underwritten rights issue, resulting in a year-end cash balance of NOK 179.7-180 million and runway into 2027.
Appointed Dr. Ramzi Amri as CFO, bringing significant medical, pharma, and financial expertise.
Ongoing Phase II ovarian cancer trial recruited 26 patients by year-end, with expanded sites in Europe and the US and strong recruitment momentum into 2026.
Financial highlights
Year-end cash position of NOK 179.7-180 million, significantly higher than previous year, providing runway into 2027.
2H 2025 operating loss of NOK 106.3 million, mainly due to increased clinical activity and merger-related expenses.
2H 2025 operating revenue: NOK 16-16.1 million, primarily from Artbio agreement.
2H 2025 operating expenses: NOK 122-122.4 million, driven by clinical trial costs and merger expenses.
One-off non-cash expense of NOK 21.5-21.6 million from reverse merger, representing about 18-20% of 2025 operating expenses.
Outlook and guidance
Cash runway extends beyond planned Phase II ovarian study analysis, supporting clinical and commercial development into 2027.
Focus on disciplined cash management, execution of Phase II trial, and evaluation of strategic opportunities.
Preparing for future financing and strategic partnerships to support Phase III development.
Final Phase II ovarian cancer trial readout expected in 2028, with interim analysis late 2026.
Protocol amendments and new sites expected to further strengthen Phase II recruitment in 2026.
Why target HRD negative ovarian cancer patients?
Future financing and partnering strategy beyond Phase 2
Impact of FDA dose optimization guidance on Radspherin
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Oncoinvent earnings date
Q2 202627 Aug, 2026
Oncoinvent
Next Oncoinvent earnings date
Q2 202627 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BerGenBio ASA is a clinical-stage biopharmaceutical company based in Bergen, Norway, focused on developing innovative therapies for aggressive diseases such as cancer and severe respiratory infections. The company specializes in AXL kinase inhibitors, with its lead product, Bemcentinib, currently undergoing clinical trials for non-small cell lung cancer (NSCLC) and severe respiratory conditions. Another key asset, Tilvestamab, is a monoclonal antibody targeting AXL, being investigated for the treatment of ovarian cancer. BerGenBio is leveraging its expertise in AXL biology to create treatments that can potentially improve outcomes in diseases characterized by drug resistance and immune evasion. The company's strategy includes partnerships with clinical sites and biopharma firms to advance its drug pipeline. The company is headquartered in Bergen, Norway, and its shares are traded on the Oslo Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage